Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02026401 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis
A Phase 2 study, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT02026401: Completed Phase 2 study, sponsored by NGM Biopharmaceuticals.
NCT02026401 is a Phase 2 study that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 45 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02026401, a Phase 2 study, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Biliary Cirrhosis.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL NGM282
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
What the finished NCT02026401 record still lists
NCT02026401 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02026401 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02026401 about?
NCT02026401 is a clinical study titled "Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis". The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Biliary Cirrhosis.
What is the current status of trial NCT02026401?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2014-02. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02026401?
The interventions under investigation include: Placebo (BIOLOGICAL), NGM282 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02026401?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02026401's enrollment target sits among peer trials
45 1296th of 2000 higher than 679 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia